Polymyalgia Rheumatica clinical trials
The registry lists 68 studies for Polymyalgia Rheumatica across more than 10 countries. 22 are recruiting or about to start. 43 of them are mainly about Polymyalgia Rheumatica (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05.
Get an email when these change. Save the Polymyalgia Rheumatica studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
University Hospital, Brest (10) · Novartis Pharmaceuticals (5) · University of Bonn (3) · Sparrow Pharmaceuticals (2) · Sint Maartenskliniek (2) · Sanofi (2) · Kresten Krarup Keller (2) · Aarhus University Hospital (2)
What is being tested here
Drugs under test in Polymyalgia Rheumatica studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Hydrocortisone | 2 | 0 | 2 |
| Secukinumab | 1 | 3 | 6 |
| Tocilizumab | 1 | 2 | 5 |
| Rituximab | 1 | 2 | 3 |
| Tofacitinib | 1 | 1 | 3 |
| Abatacept | 1 | 1 | 2 |
| Etanercept | 1 | 1 | 2 |
| Sarilumab | 1 | 2 | 2 |
| Leflunomide | 1 | 1 | 2 |
| Infliximab | 1 | 1 | 2 |
Drug classes tested here Corticosteroids 2 open · JAK inhibitors 2 open · Tyrosine kinase inhibitors (TKIs) 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4, phase 3 first
- Jan 2027Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse · Phase 3 · Sint Maartenskliniek
- Mar 2027Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica · Washington University School of Medicine
- Apr 2027DNA Methylation in PMR · Dartmouth-Hitchcock Medical Center
- Oct 2027Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ) · Centre Hospitalier Universitaire Dijon
Who these studies take
Of the 16 Polymyalgia Rheumatica studies recruiting now, 15 (94%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 1 (6%) for men only; 4 (25%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 6 (38%) | 6 (38%) |
| 30 | 6 (38%) | 6 (38%) |
| 40 | 6 (38%) | 6 (38%) |
| 50 | 15 (94%) | 16 (100%) |
| 65 | 15 (94%) | 16 (100%) |
| 75 | 15 (94%) | 16 (100%) |
| 85 | 15 (94%) | 16 (100%) |
Across all 68 studies, recruiting or not: 1% stop at 75 or younger and 1% at 65; 3% take children; 0% are for women only and 1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 68. Browse all 68 → or search them.
- Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia RheumaticaRecruitingNCT07749547Not applicable1 country
- Sarilumab Efficacy and Safety in Adults With Early Polymyalgia RheumaticaRecruitingNCT07286214Phase 310 countries
- A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor ImmunotherapyRecruitingNCT066471341 country
- DNA Methylation in PMRNot yet recruitingNCT07748195
- Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumaticaRecruitingNCT07279688Phase 31 country
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 21 country
- Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE)Not yet recruitingNCT071321641 country
- Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal InsufficiencyRecruitingNCT05435781Phase 41 country
- Rheumatology Patient Registry and BiorepositoryRecruitingNCT044020861 country
- Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia RheumaticaNot yet recruitingNCT073944781 country
- Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid TreatmentRecruitingNCT05193396Phase 41 country
- Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia RheumaticaRecruitingNCT070104841 country
- Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)RecruitingNCT066096681 country
- Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and EfficacyRecruitingNCT071500001 country
- AYLo - AutoimmunitY and Loss of yRecruitingNCT066960271 country
- Assessing Biomarker in Giant Cell Arteritis and Polymyalgia RheumaticRecruitingNCT064601421 country
- Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell ArteritisRecruitingNCT054794481 country
- Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)RecruitingNCT041029301 country
- Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic DiseasesEnrolling by invitationNCT06763783Phase 41 country
- A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.Not yet recruitingNCT067665521 country
- Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia RheumaticaNot yet recruitingNCT065583571 country
- DANIsh VASculitis Database (DANIVAS)RecruitingNCT059357091 country
- Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)Active, not recruitingNCT06331312Phase 322 countries
- Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia RheumaticaCompletedNCT06172361Phase 31 country
- Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)Active, not recruitingNCT07670546Phase 31 country
- Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)CompletedNCT05767034Phase 326 countries
- PRediction Of DIverse Glucocorticoids toxIcity OUtcomeSActive, not recruitingNCT046644651 country
- Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORSCompletedNCT03632187Phase 31 country
- Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.CompletedNCT060115121 country
- Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMRCompletedNCT06130540Phase 16 countries
- Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical RemissionCompletedNCT05380453Phase 31 country
- Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR RelapseActive, not recruitingNCT05533164Phase 31 country
- Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently DiagnosedCompletedNCT05533125Phase 31 country
- Treat-to-target Prednisolon Taper in Patients With Polymyalgia RheumaticaActive, not recruitingNCT05636501Not applicable1 country
- Improved Diagnostics and Monitoring of Polymyalgia RheumaticaActive, not recruitingNCT045195801 country
- A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)TerminatedNCT06281236Phase 11 country
- A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)CompletedNCT05436652Phase 22 countries
- Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia RheumaticaCompletedNCT055423161 country
- A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154TerminatedNCT04972968Phase 215 countries
- PatientSpot Formerly Known as ArthritisPowerStatus unknownNCT038409281 country
- Immunopathology of Polymyalgia Rheumatica on Shoulder Bursae's BiopsiesCompletedNCT04727879Not applicable1 country
- Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune DiseaseTerminatedNCT03656627Phase 11 country
- Melanocortin Gene Expression in Lymphocytes of Polymyalgia PatientsCompletedNCT05681676
- The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia AreataCompletedNCT042395211 country
- Tofacitinib as a GC Sparing Agent for Polymyalgia RheumaticaCompletedNCT04799262Phase 21 country
- Timed Release Tablet Prednisone in Polymyalgia RheumaticaCompletedNCT00836810Phase 2/31 country
- Aetiology of TemporaL Arteritis StudyWithdrawnNCT02584517
- Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia RheumaticaTerminatedNCT03600818Phase 317 countries
- Polymyalgia Rheumatica Associated to Primary Sjogren SyndromeStatus unknownNCT053129441 country
- A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia RheumaticaTerminatedNCT01364389Phase 24 countries